First National Trust Co Has $4.02 Million Stock Holdings in Pfizer Inc. $PFE

First National Trust Co grew its holdings in Pfizer Inc. (NYSE:PFE) by 0.4% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 165,789 shares of the biopharmaceutical company’s stock after buying an additional 703 shares during the quarter. First National Trust Co’s holdings in Pfizer were worth $4,019,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Signet Investment Advisory Group Inc. raised its holdings in Pfizer by 2.4% during the 2nd quarter. Signet Investment Advisory Group Inc. now owns 135,312 shares of the biopharmaceutical company’s stock worth $3,280,000 after purchasing an additional 3,194 shares during the last quarter. Clark Asset Management LLC acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $221,000. Conscious Wealth Investments LLC grew its position in shares of Pfizer by 0.5% during the 2nd quarter. Conscious Wealth Investments LLC now owns 140,957 shares of the biopharmaceutical company’s stock worth $3,425,000 after buying an additional 706 shares during the period. Taylor Financial Group Inc. grew its position in shares of Pfizer by 25.6% during the 2nd quarter. Taylor Financial Group Inc. now owns 13,806 shares of the biopharmaceutical company’s stock worth $335,000 after buying an additional 2,815 shares during the period. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund grew its position in shares of Pfizer by 26.1% during the 2nd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 1,001,271 shares of the biopharmaceutical company’s stock worth $24,271,000 after buying an additional 207,000 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Pfizer stock opened at $24.76 on Tuesday. The firm has a market capitalization of $140.75 billion, a P/E ratio of 13.17, a PEG ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.17. The business has a 50-day moving average of $24.86 and a 200-day moving average of $24.21. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the firm earned $0.60 EPS. Pfizer’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s payout ratio is currently 91.49%.

Wall Street Analysts Forecast Growth

PFE has been the subject of several analyst reports. Bank of America lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Morgan Stanley decreased their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. Finally, Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.